Clinical Trial Detail

NCT ID NCT03033914
Title A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Vinblastine + Nivolumab

Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab

Age Groups: adult senior

No variant requirements are available.